Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2014
Exchange: NASDAQ
Website: sesenbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2021 | Buy → Neutral | HC Wainwright & Co. |
Company hires four experienced leaders across commercial, medical and human resources functions as it works towards launch readiness Company remains on track for potential approval of Vicineum™ in the US in August 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its senior leadership team with the appointment of experienced industry leaders to several key roles: Patricia Drake to Chief Commercial Officer Steve Barbera to Vice President, Market Access Julie Hoff to Vice President, Human Resources Dewey McLin to Vice President, Medical Affairs "I a
Company appoints experienced commercial leader, Lisa LaMond, to oversee sales strategy and execution Selected Syneos Health® as partner for field sales execution in the US Company remains on track for potential approval in the US in August 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced commercial industry leader, Lisa LaMond, as Vice President, Sales and Corporate Systems. The Company also announced its engagement of leading contract sales organization (CSO), Syneos Health, for field sales support
10-Q - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
10-Q - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
EFFECT - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
424B5 - Carisma Therapeutics Inc. (0001485003) (Filer)
POS AM - Carisma Therapeutics Inc. (0001485003) (Filer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
HC Wainwright & Co. downgraded Sesen Bio from Buy to Neutral
Canaccord Genuity resumed coverage of Sesen Bio with a rating of Buy and set a new price target of $7.00
HC Wainwright reiterated coverage of Sesen Bio with a rating of Buy and set a new price target of $8.00 from $2.25 previously
Canaccord Genuity reiterated coverage of Sesen Bio with a rating of Buy and set a new price target of $7.00 from $5.00 previously
Canaccord Genuity resumed coverage of Sesen Bio with a rating of Buy
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support of the merger with Carisma. The fact th
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis's Recommendations to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that leading independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), in advance of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. In reaching its concl
Report Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards' Belief That Carisma Merger Maximizes Value for Stockholders Reiterates Support from Several of Sesen Bio's Largest Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that Institutional Shareholder Services ("ISS") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Compan
Sesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" the Value Maximizing Merger on the WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that BML Investment Partners, L.P. ("BML"), one of Sesen Bio's top stockholders, intends to vote all of its shares in support of the Company's pending merger with Carisma Therapeutics Inc. ("Carisma"). BML owned approximately 4.1% of the Company's outstanding common stock as of the close of business on January 17, 2023, the record date for the Special Meeting of Stockholders. Brad Leonard, Managing Member of BML, said, "Sesen Bio has engaged extensively with stockholders, and we are co
Amend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Contingent Value Right for Vicineum to March 31, 2027 Bradley L. Radoff and Michael Torok to Vote Shares in Support of Transaction Michael Torok to Join Carisma Board of Directors as Only Sesen Bio Representative Special Meeting of Stockholders to Approve Merger to be Held on March 2, 2023 Sesen Bio, Inc. (NASDAQ:SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the companies have reached a voting and support agreement (the "Support Agreement") with Bradle
Highlights Board's Robust Strategic Review Process and Unanimous Determination that Carisma Merger Maximizes Value for Stockholders Urges Stockholders to Vote "FOR" Transaction Ahead of Special Meeting of Stockholders on March 2, 2023 Sesen Bio, Inc. (NASDAQ:SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. ("Carisma"). The presentation can be found at www.SesenBioandCarisma.com. Highlights of the presentation include: The merger with Carisma delivers substantial and immediate value for Sesen Bio stockholders, which is meaningfully better than the alternative of dissolution and liquidation Expected special one-time cash
Company Calls Out Misrepresentations from Investor Group Sesen Bio, Inc. (NASDAQ:SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the "Investor Group"): Our attempts to engage with the Investor Group have been driven by our belief that an amicable resolution and successful transaction are in the best interest of our stockholders. Despite the fact that Mr. Radoff built his current position after the merger was announced, and the continued efforts by the Investor G
Discloses Recent Offer to Provide Paid Advisory Roles to Messrs. Radoff and Torok – Major Stockholders of Sesen Bio – in Exchange for Their Support of the Proposed Merger of Sesen Bio and Carisma Reiterates Intent to Vote AGAINST the Proposed Merger Bradley L. Radoff and Michael Torok (together with their affiliates, the "Investor Group" or "we"), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio"), today issued the following open letter to the Boards of Directors (collectively, the "Boards") of Sesen Bio and Carisma Therapeutics Inc. ("Carisma" and together with Sesen Bio, the "Companies"): Members of the Sesen Bio and Carisma Boards
Schedules March 2, 2023, Special Meeting of Stockholders to Vote on Merger Launches www.SesenBioandCarisma.com, Providing Additional Information for Stockholders Sesen Bio, Inc. (NASDAQ:SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about January 24, 2023. The special meeting of stockholders will be held excl
Highlights Expected Special Cash Dividend of Approximately $70 Million, and Upside of CVR and Ownership of Combined Company Sesen Bio, Inc. (NASDAQ:SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) as the best path forward for stockholders. The Sesen Bio Board of Directors remains confident that the pending merger with Carisma represents the most value maximizing path forward. The Board, in consultation with its financial and legal advisors, undertook a four-month comprehensive review of strategic alternatives, including evaluating a merger, sale of assets, resumption of R&D a
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support of the merger with Carisma. The fact th
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis's Recommendations to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that leading independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), in advance of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. In reaching its concl
Report Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards' Belief That Carisma Merger Maximizes Value for Stockholders Reiterates Support from Several of Sesen Bio's Largest Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that Institutional Shareholder Services ("ISS") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Compan
Sesen Bio, Inc. (NASDAQ:SESN) today announced that members of its management team will host a fireside chat with members of the Carisma Therapeutics Inc. ("Carisma") management team on Tuesday, February 21, 2023, at 8:00 am ET. The discussion will cover Sesen Bio's pending merger with Carisma, as well as Carisma's corporate strategy and clinical programs. Sesen Bio stockholders can submit questions in advance to [email protected]. The webcast, which can be accessed on the Events and Presentations link on the Sesen Bio website, will be broadcast live and a replay will be available following the conclusion of the event. As previously announced, Sesen Bio will hold the Special Meeting of Stock
Sesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" the Value Maximizing Merger on the WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that BML Investment Partners, L.P. ("BML"), one of Sesen Bio's top stockholders, intends to vote all of its shares in support of the Company's pending merger with Carisma Therapeutics Inc. ("Carisma"). BML owned approximately 4.1% of the Company's outstanding common stock as of the close of business on January 17, 2023, the record date for the Special Meeting of Stockholders. Brad Leonard, Managing Member of BML, said, "Sesen Bio has engaged extensively with stockholders, and we are co
Amend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Contingent Value Right for Vicineum to March 31, 2027 Bradley L. Radoff and Michael Torok to Vote Shares in Support of Transaction Michael Torok to Join Carisma Board of Directors as Only Sesen Bio Representative Special Meeting of Stockholders to Approve Merger to be Held on March 2, 2023 Sesen Bio, Inc. (NASDAQ:SESN) and Carisma Therapeutics Inc. (Carisma), a privately-held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the companies have reached a voting and support agreement (the "Support Agreement") with Bradle
Highlights Board's Robust Strategic Review Process and Unanimous Determination that Carisma Merger Maximizes Value for Stockholders Urges Stockholders to Vote "FOR" Transaction Ahead of Special Meeting of Stockholders on March 2, 2023 Sesen Bio, Inc. (NASDAQ:SESN) today filed an investor presentation highlighting its value maximizing merger with Carisma Therapeutics Inc. ("Carisma"). The presentation can be found at www.SesenBioandCarisma.com. Highlights of the presentation include: The merger with Carisma delivers substantial and immediate value for Sesen Bio stockholders, which is meaningfully better than the alternative of dissolution and liquidation Expected special one-time cash
Company Calls Out Misrepresentations from Investor Group Sesen Bio, Inc. (NASDAQ:SESN) today issued the following statement reiterating the Company's confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the "Investor Group"): Our attempts to engage with the Investor Group have been driven by our belief that an amicable resolution and successful transaction are in the best interest of our stockholders. Despite the fact that Mr. Radoff built his current position after the merger was announced, and the continued efforts by the Investor G
Discloses Recent Offer to Provide Paid Advisory Roles to Messrs. Radoff and Torok – Major Stockholders of Sesen Bio – in Exchange for Their Support of the Proposed Merger of Sesen Bio and Carisma Reiterates Intent to Vote AGAINST the Proposed Merger Bradley L. Radoff and Michael Torok (together with their affiliates, the "Investor Group" or "we"), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio"), today issued the following open letter to the Boards of Directors (collectively, the "Boards") of Sesen Bio and Carisma Therapeutics Inc. ("Carisma" and together with Sesen Bio, the "Companies"): Members of the Sesen Bio and Carisma Boards
Schedules March 2, 2023, Special Meeting of Stockholders to Vote on Merger Launches www.SesenBioandCarisma.com, Providing Additional Information for Stockholders Sesen Bio, Inc. (NASDAQ:SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company's pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies. Sesen Bio will commence mailing the definitive proxy statement / prospectus to its stockholders on or about January 24, 2023. The special meeting of stockholders will be held excl
Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares increased by 114.3% to $1.05 during Monday's pre-market session. The company's market cap stands at $15.8 million. BridgeBio Pharma (NASDAQ:BBIO) stock moved upwards by 56.39% to $17.0. The market value of their outstanding shares is at $2.5 billion. vTv Therapeutics (NASDAQ:VTVT) stock increased by 48.51% to $1.2. The company's market cap stands at $97.7 million. Kala Pharmaceuticals (NASDAQ:KALA) shares increased by 27.46% to $21.35. The company's market cap stands at $39.9 million. The company's, Q4 earnings came out yesterday. TCR2 Therapeutics (NASDAQ:TCRR) shares rose 25.61% to $1.52. The market value of their outstanding shares
Gainers Secoo Holding Limited (NASDAQ:SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday. Entera Bio Ltd. (NASDAQ:ENTX) rose 43.1% to $1.46 in pre-market trading after dropping 5% on Friday. Entera Bio recently announced the FDA's acceptance of a Type D meeting review to affirm design of the pivotal, Phase 3 protocol for EB613 PTH mini tablets, as the first oral osteoanabolic treatment of post-menopausal osteoporosis. BuzzFeed, Inc. (NASDAQ:BZFD) rose 20.7% to $1.87 in pre-market trading. BuzzFeed is expected to release its Q4 financial results on Monday, March 13, 2023, after the closing bell. BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 12.5% to $2.8
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support of the merger with Carisma. The fact tha
On February 24, 2023, Sesen Bio, Inc. (the “Company”) received a determination from The Nasdaq Stock Market LLC (“Nasdaq”) Office of General Counsel that the Nasdaq Hearings Panel (the “Panel”) has granted the Company an exception from the Company’s non-compliance with the $1.00 bid price requirement (Nasdaq Listing Rule 5550(a)(2)) to complete the proposed merger with Carisma Therapeutics Inc. (“Carisma”) by March 10, 2023. Pursuant to Nasdaq Listing Rule 5110(a), the Company must demonstrate compliance with all initial listing requirements of Nasdaq upon the closing of the proposed merger. The Company was scheduled for a hearing with the Panel on March 16, 2023. The Company is seeking
Gainers Blue Water Vaccines (NASDAQ:BWV) stock moved upwards by 46.1% to $1.71 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 52.2 million, which is 15191.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $26.4 million. Fusion Pharmaceuticals (NASDAQ:FUSN) shares rose 18.5% to $4.29. Fusion Pharmaceuticals's stock is trading at a volume of 12.1 million shares as of 12:30 EST. This is 13663.5% of its average full-day volume over the last 100 days. The company's market cap stands at $192.0 million. Geovax Labs (NASDAQ:GOVX) shares rose 17.17% to $0.91. As of 12:30 EST, this security is trading
Gainers Rubius Therapeutics (NASDAQ:RUBY) stock increased by 31.5% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $22.5 million. Fusion Pharmaceuticals (NASDAQ:FUSN) stock rose 23.75% to $4.48. The market value of their outstanding shares is at $200.5 million. Blue Water Vaccines (NASDAQ:BWV) stock increased by 21.36% to $1.42. The company's market cap stands at $21.9 million. Creative Medical Tech (NASDAQ:CELZ) shares rose 19.93% to $0.88. The company's market cap stands at $12.3 million. Sesen Bio (NASDAQ:SESN) shares rose 11.49% to $0.6. The company's market cap stands at $121.6 million. Ikena Oncology (NASDAQ:IKNA) shares increased by 10.9% to $3.6
Company Remains Focused on Significant Benefits of Pending Merger with Carisma Delisting Notice Underscores Potential for Corporate Dissolution if Merger is not Approved by Stockholders Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company") today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company's non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company's common stock is subject to delisting. The Company today issued the following statement: The receipt of this notice from Nasdaq underscores our belief that, without the pen
Discloses Recent Offer to Provide Paid Advisory Roles to Messrs. Radoff and Torok – Major Stockholders of Sesen Bio – in Exchange for Their Support of the Proposed Merger of Sesen Bio and Carisma
SC 13G/A - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13G/A - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13D - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13G - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13G - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13D - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13D/A - Sesen Bio, Inc. (0001485003) (Subject)
SC 13D/A - Sesen Bio, Inc. (0001485003) (Subject)